Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database
In the context of a varenicline shortage, the pharmacovigilance data confirmed the risk of smoking relapse and/or cessation failure in patients with a strong addiction to cigarettes. Given the role of smoking exposure in respiratory, cancer and cardiovascular risk, it is vitally important that the availability of this medicine is ensured. Solutions, such as the importation of alternatives produced by other brands that pass the tests for impurity quantification, may prevent the risk in this context.
Authors
- Marie Briet (ORCID: https://orcid.org/0000-0003-3738-5998)
- Pierre Brunel
- A. Gentil
- Ivan Berlin (ORCID: https://orcid.org/0000-0002-5928-5616)
- Delphine Bourneau‐Martin (ORCID: https://orcid.org/0000-0003-4103-7558)
- Bénédicte Lebrun-Vignes
- Amélie Lepert
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Université d'Angers (FR)
Publication Details
- Journal
- Therapies
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1016/j.therap.2025.02.009
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.31